1
|
Arao M, Yajima T. Computed tomography-based abdominal sarcopenic indices and bio-impedance analysis-based skeletal muscle mass index in hemodialyzed patients. Clin Nutr ESPEN 2024; 59:21-28. [PMID: 38220378 DOI: 10.1016/j.clnesp.2023.11.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2023] [Revised: 10/31/2023] [Accepted: 11/17/2023] [Indexed: 01/16/2024]
Abstract
BACKGROUND AND AIMS Information about muscle wasting in hemodialyzed patients evaluated using computed tomography (CT) is limited. The present study aimed to examine the relationships between CT-based abdominal sarcopenic indices and bio-impedance analysis (BIA)-based skeletal muscle mass index (SMMI) in these patients. METHODS A total of 100 consecutive maintenance hemodialyzed patients who underwent CT and BIA were included. The psoas muscle index (PMI), paraspinous muscle index (PSMI), and abdominal skeletal muscle index (ASMI) were calculated by adjusting each muscle area to the height square. The psoas muscle thickness per height (PMTH) was measured using a single cross-sectional CT image obtained at the level of the third lumbar vertebra. The relationships between these CT-based sarcopenic indices and the BIA-based SMMI were examined. Moreover, the diagnostic values of these CT-based indices for BIA-defined muscle wasting (defined by the sex-specific SMMI: males, <7.0 kg/m2; females, <5.7 kg/m2) were investigated. RESULTS The PMI, PMTH, PSMI, and ASMI were significantly correlated with the SMMI (r = 0.678, 0.760, 0.708, and 0.785, respectively; p < 0.0001 for all). Twenty-eight patients with reduced muscle mass determined by BIA were identified. After age-sex adjustment, a multivariate logistic regression analysis revealed that the C-statistics of the PMI, PMTH, PSMI, and ASMI for the diagnosis of low muscle mass were 0.863 (p = 0.0099), 0.870 (p = 0.013), 0.891 (p = 0.040), and 0.950 (reference), respectively. CONCLUSIONS CT-based abdominal sarcopenic indices presented here may be useful for evaluating muscle wasting in hemodialyzed patients; the ASMI may be the most recommended sarcopenic index for such evaluations.
Collapse
Affiliation(s)
- Maiko Arao
- Department of Nephrology, Matsunami General Hospital, Gifu, 501-6062, Japan
| | - Takahiro Yajima
- Department of Nephrology, Matsunami General Hospital, Gifu, 501-6062, Japan.
| |
Collapse
|
2
|
Chang YL, Chen YT, Wang HH, Chiang PH, Cheng YT, Kang CH, Chuang YC, Lee WC, Yang WC, Liu HY, Su YL, Huang CC, Tse SM, Luo HL. The prognostic impact of lymphovascular invasion for upper urinary tract urothelial carcinoma: A propensity score-weighted analysis. Medicine (Baltimore) 2023; 102:e33485. [PMID: 37058048 PMCID: PMC10101277 DOI: 10.1097/md.0000000000033485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Accepted: 03/20/2023] [Indexed: 04/15/2023] Open
Abstract
Lymphovascular invasion (LVI) predicts poor survival in patients with pathologically localized or locally advanced upper urinary tract urothelial carcinoma (UT-UC). However, LVI is associated with high tumor grade, tumor necrosis, advanced tumor stage, tumor location, concomitant carcinoma in situ, lymph node metastasis, and sessile tumor architecture. These factors might interfere with the analysis of the impact of LVI on oncological prognosis. To address this, this study aimed to clarify the relationship between LVI and patient prognosis in UT-UC using propensity score weighting. Data were collected from 789 patients with UT-UC treated with radical nephroureterectomy without chemotherapy. We evaluated the significance of LVI in predicting metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS) using propensity score weighting. All weighted baseline characteristics included in the propensity score model were balanced between the LVI (+) and LVI (-) groups. The MFS, CSS, and OS were all significantly poorer in the LVI (+) group. For patients without LVI, the 5-year MFS, CSS, and OS rates were 65.3%, 73.1%, and 67.3%, respectively, whereas the corresponding rates were 50.2%, 63.8 %, and 54.6%, respectively, for patients with LVI. (all P < .001). For patients without LVI, the 10-year MFS, CSS, and OS rates were 61.5%, 69.6%, and 59.2%, respectively, whereas those for patients with LVI were 44.5%, 57.0%, and 42.7%, respectively (all P < .001). LVI is an important pathological feature that predicts metastasis development and worse survival outcome after radical surgery in UT-UC patients.
Collapse
Affiliation(s)
- Yin Lun Chang
- Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Yen Ta Chen
- Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Hung Hen Wang
- Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Po Hui Chiang
- Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Yuan Tso Cheng
- Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Chih Hsiung Kang
- Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Yao Chi Chuang
- Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Wei Chin Lee
- Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Wen Chou Yang
- Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Hui Ying Liu
- Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Yu Li Su
- Department of Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Chun Chieh Huang
- Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Sung Min Tse
- Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Hao Lun Luo
- Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| |
Collapse
|
3
|
Pickl C, Engelmann S, Girtner F, Gužvić M, van Rhijn BWG, Hartmann V, Holbach S, Kälble S, Haas M, Rosenhammer B, Breyer J, Burger M, Mayr R. Body Composition as a Comorbidity-Independent Predictor of Survival following Nephroureterectomy for Urothelial Cancer of the Upper Urinary Tract. Cancers (Basel) 2023; 15:cancers15020450. [PMID: 36672398 PMCID: PMC9857333 DOI: 10.3390/cancers15020450] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 01/07/2023] [Accepted: 01/08/2023] [Indexed: 01/12/2023] Open
Abstract
Radical nephroureterectomy (NUE) is the gold standard treatment for high-risk urothelial cancer of the upper urinary tract (UTUC). Besides sarcopenia and frailty, fat distribution is moving increasingly into focus. Components of body composition were assessed in patients undergoing NUE due to UTUC. The study cohort included 142 patients. By using CT-based measurements, the skeletal muscle index (SMI), subcutaneous adipose tissue index (SATI), and visceral adipose tissue index (VATI) were measured at the height of the third lumbar vertebra. Overall survival (OS) and cancer-specific survival (CSS) were estimated using univariable und multivariable Cox regression models. The prevalence of sarcopenia in the study population (n = 142) was 37%. OS and CSS were significantly reduced in sarcopenic patients. In the multivariable cox regression analysis, including age, ACE-27, T-stage, R-stage, LVI and necrosis, sarcopenia remained a significant risk factor of OS (HR, 1.77; 95% CI 1.02-3.07; p = 0.042) and CSS (HR, 2.17; 95% CI 1.18-3.99; p = 0.012). High visceral adipose tissue seems to be protective, although not statistically significant. Sarcopenia is a comorbidity-independent risk factor in patients who underwent NUE due to UTUC. Visceral fat represents a potentially protective factor. These results suggest that specific factors of body composition can be used for better risk stratification.
Collapse
Affiliation(s)
- Christoph Pickl
- Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany
| | - Simon Engelmann
- Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany
| | - Florian Girtner
- Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany
| | - Miodrag Gužvić
- Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany
| | - Bas W. G. van Rhijn
- Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany
- Department of Surgical Oncology (Urology), Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands
| | - Valerie Hartmann
- Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany
| | - Sonja Holbach
- Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany
| | - Sebastian Kälble
- Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany
| | - Maximilian Haas
- Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany
| | - Bernd Rosenhammer
- Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany
| | - Johannes Breyer
- Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany
| | - Maximilian Burger
- Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany
| | - Roman Mayr
- Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany
- Correspondence:
| |
Collapse
|
4
|
Ligibel JA, Schmitz KH, Berger NA. Sarcopenia in aging, obesity, and cancer. Transl Cancer Res 2020; 9:5760-5771. [PMID: 33163373 PMCID: PMC7643855 DOI: 10.21037/tcr-2019-eaoc-05] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Accepted: 06/03/2020] [Indexed: 12/25/2022]
Abstract
Sarcopenia, defined as loss of muscle mass, strength and physical performance, is a hallmark of aging and is invariably associated with perturbation of amino acid metabolism, increased muscle protein catabolism relative to anabolism, and loss of muscle fibers. Sarcopenia may be associated with general loss of body mass, or it may also occur along with obesity [sarcopenic obesity (SO)]. Although sarcopenia is associated with multiple comorbidities in older adults, its effects may even be more severe in patients with malignant disease where it has been shown to contribute to poor surgical outcomes, increased chemotherapy toxicity associated with both cytotoxic and targeted agents, as well as adversely impacting survival. While development of sarcopenia is a common age-related phenomenon, the associated catabolic processes appear to be promoted by physical inactivity, inadequate nutrition, and systemic low-grade inflammation, as well as intrinsic muscle and molecular changes, including mitochondrial dysfunction and impaired muscle stem cell regenerative capacity. Increased physical activity and adequate protein intake can reduce incidence and severity of sarcopenia in cancer patients, but many older cancer patients do not meet physical activity and nutrition recommendations, and cancer treatment can make it more difficult to make favorable lifestyle changes. Sarcopenia is discussed in terms of its adverse clinical consequences in older subjects and particularly, in older patients with cancer. Contributions of lifestyle, molecular, and cellular factors are likewise reviewed with suggestions for interventions to improve sarcopenia and its comorbid sequalae.
Collapse
Affiliation(s)
- Jennifer A. Ligibel
- Division of Women’s Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Kathryn H. Schmitz
- Department Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA
| | - Nathan A. Berger
- Department Medicine, Biochemistry, Oncology, Genetics & Genome Sciences, Center for Science, Health and Society, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA
| |
Collapse
|
5
|
Miyake M, Hori S, Itami Y, Oda Y, Owari T, Fujii T, Ohnishi S, Morizawa Y, Gotoh D, Nakai Y, Anai S, Torimoto K, Tanaka N, Fujimoto K. Supplementary Oral Anamorelin Mitigates Anorexia and Skeletal Muscle Atrophy Induced by Gemcitabine Plus Cisplatin Systemic Chemotherapy in a Mouse Model. Cancers (Basel) 2020; 12:cancers12071942. [PMID: 32709007 PMCID: PMC7409153 DOI: 10.3390/cancers12071942] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 07/02/2020] [Accepted: 07/15/2020] [Indexed: 02/08/2023] Open
Abstract
Chemotherapy-induced adverse effects can reduce the relative dose intensity and quality of life. In this study, we investigated the potential benefit of supplementary anamorelin and 5-aminolevulinic acid (5-ALA) as preventive interventions against a gemcitabine and cisplatin (GC) combination chemotherapy-induced adverse effects in a mouse model. Non-cancer-bearing C3H mice were randomly allocated as follows and treated for 2 weeks—(1) non-treated control, (2) oral anamorelin alone, (3) oral 5-ALA alone, (4) gemcitabine and cisplatin (GC) chemotherapy, (5) GC plus anamorelin, and (6) GC plus 5-ALA. GC chemotherapy significantly decreased body weight, food intake, skeletal muscle mass and induced severe gastric mucositis, which resulted in decreased ghrelin production and blood ghrelin level. The supplementation of oral anamorelin to GC chemotherapy successfully mitigated decrease of food intake during the treatment period and body weight loss at day 8. In addition, analysis of the resected muscles and stomach revealed that anamorelin suppressed chemotherapy-induced skeletal muscle atrophy by mediating the downregulation of forkhead box protein O-1 (FOXO1)/atrogin-1 signaling and gastric damage. Our findings suggest the preventive effect of anamorelin against GC combination chemotherapy, which was selected for patients with some types of advanced malignancies in clinical practice.
Collapse
Affiliation(s)
- Makito Miyake
- Department of Urology, Nara Medical University School of Medicine, Nara 634-8522, Japan; (S.H.); (Y.I.); (Y.O.); (T.O.); (S.O.); (Y.M.); (D.G.); (Y.N.); (S.A.); (K.T.); (N.T.); (K.F.)
- Correspondence: ; Tel.: +81-744-22-3051 (ext. 2338); Fax: +81-744-22-9282
| | - Shunta Hori
- Department of Urology, Nara Medical University School of Medicine, Nara 634-8522, Japan; (S.H.); (Y.I.); (Y.O.); (T.O.); (S.O.); (Y.M.); (D.G.); (Y.N.); (S.A.); (K.T.); (N.T.); (K.F.)
| | - Yoshitaka Itami
- Department of Urology, Nara Medical University School of Medicine, Nara 634-8522, Japan; (S.H.); (Y.I.); (Y.O.); (T.O.); (S.O.); (Y.M.); (D.G.); (Y.N.); (S.A.); (K.T.); (N.T.); (K.F.)
| | - Yuki Oda
- Department of Urology, Nara Medical University School of Medicine, Nara 634-8522, Japan; (S.H.); (Y.I.); (Y.O.); (T.O.); (S.O.); (Y.M.); (D.G.); (Y.N.); (S.A.); (K.T.); (N.T.); (K.F.)
| | - Takuya Owari
- Department of Urology, Nara Medical University School of Medicine, Nara 634-8522, Japan; (S.H.); (Y.I.); (Y.O.); (T.O.); (S.O.); (Y.M.); (D.G.); (Y.N.); (S.A.); (K.T.); (N.T.); (K.F.)
| | - Tomomi Fujii
- Department of Diagnostic Pathology, Nara Medical University School of Medicine, Nara 634-8521, Japan;
| | - Sayuri Ohnishi
- Department of Urology, Nara Medical University School of Medicine, Nara 634-8522, Japan; (S.H.); (Y.I.); (Y.O.); (T.O.); (S.O.); (Y.M.); (D.G.); (Y.N.); (S.A.); (K.T.); (N.T.); (K.F.)
| | - Yosuke Morizawa
- Department of Urology, Nara Medical University School of Medicine, Nara 634-8522, Japan; (S.H.); (Y.I.); (Y.O.); (T.O.); (S.O.); (Y.M.); (D.G.); (Y.N.); (S.A.); (K.T.); (N.T.); (K.F.)
| | - Daisuke Gotoh
- Department of Urology, Nara Medical University School of Medicine, Nara 634-8522, Japan; (S.H.); (Y.I.); (Y.O.); (T.O.); (S.O.); (Y.M.); (D.G.); (Y.N.); (S.A.); (K.T.); (N.T.); (K.F.)
| | - Yasushi Nakai
- Department of Urology, Nara Medical University School of Medicine, Nara 634-8522, Japan; (S.H.); (Y.I.); (Y.O.); (T.O.); (S.O.); (Y.M.); (D.G.); (Y.N.); (S.A.); (K.T.); (N.T.); (K.F.)
| | - Satoshi Anai
- Department of Urology, Nara Medical University School of Medicine, Nara 634-8522, Japan; (S.H.); (Y.I.); (Y.O.); (T.O.); (S.O.); (Y.M.); (D.G.); (Y.N.); (S.A.); (K.T.); (N.T.); (K.F.)
| | - Kazumasa Torimoto
- Department of Urology, Nara Medical University School of Medicine, Nara 634-8522, Japan; (S.H.); (Y.I.); (Y.O.); (T.O.); (S.O.); (Y.M.); (D.G.); (Y.N.); (S.A.); (K.T.); (N.T.); (K.F.)
| | - Nobumichi Tanaka
- Department of Urology, Nara Medical University School of Medicine, Nara 634-8522, Japan; (S.H.); (Y.I.); (Y.O.); (T.O.); (S.O.); (Y.M.); (D.G.); (Y.N.); (S.A.); (K.T.); (N.T.); (K.F.)
- Department of Prostate Brachytherapy, Nara Medical University School of Medicine, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Kiyohide Fujimoto
- Department of Urology, Nara Medical University School of Medicine, Nara 634-8522, Japan; (S.H.); (Y.I.); (Y.O.); (T.O.); (S.O.); (Y.M.); (D.G.); (Y.N.); (S.A.); (K.T.); (N.T.); (K.F.)
| |
Collapse
|
6
|
Aleixo GFP, Shachar SS, Nyrop KA, Muss HB, Battaglini CL, Williams GR. Bioelectrical Impedance Analysis for the Assessment of Sarcopenia in Patients with Cancer: A Systematic Review. Oncologist 2019; 25:170-182. [PMID: 32043785 DOI: 10.1634/theoncologist.2019-0600] [Citation(s) in RCA: 63] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2019] [Accepted: 10/03/2019] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND The loss of muscle mass, known as sarcopenia, is a natural process of aging that is associated with adverse health outcomes regardless of age. Because cancer is a disease of aging, interest in sarcopenia and its potential impact in multiple cancer populations has increased significantly. Bioelectrical impedance analysis (BIA) is a guideline-accepted method for sarcopenia detection. This systematic review assesses the literature pertaining to BIA use in the detection of sarcopenia in adults with cancer. MATERIALS AND METHODS In this systematic review, a search of the literature for randomized controlled trials and observational studies was conducted using MEDLINE, Cochrane CENTRAL, and EMBASE, through July 15, 2019. The study is registered at Prospero (CRD 42019130707). For study inclusion, patients had to be aged 18 years or older and diagnosed with solid or hematological neoplasia, and BIA had to be used to detect sarcopenia. RESULTS Through our search strategy, 5,045 articles were identified, of which 24 studies were selected for inclusion in the review (total number of 3,607 patients). In five studies, BIA was rated comparable to axial computed tomography (CT) scan, calf circumference, or grip strength for sarcopenia screening. In 14 studies, BIA-identified sarcopenia was associated with adverse clinical outcomes. CONCLUSION BIA is an accurate method for detecting sarcopenia in adults with cancer prior to treatment and is a viable alternative to CT, dual-energy x-ray absorptiometry, and magnetic resonance imaging in oncology clinical practice. IMPLICATIONS FOR PRACTICE Bioelectrical impedance analysis (BIA) is an attractive method for identifying sarcopenic patients in clinical practice because it provides an affordable, noninvasive test that can be completed within a few minutes during a clinic visit. BIA does not require highly skilled personnel, and results are immediately available. This systematic review summarizes the literature pertaining to BIA assessment of sarcopenia in adults with cancer, with a focus on its use in diverse cancer populations.
Collapse
Affiliation(s)
- Gabriel F P Aleixo
- Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
- Unoeste Universidade do Oeste Paulista, Presidente Prudente, São Paulo, Brazil
| | | | - Kirsten A Nyrop
- Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
| | - Hyman B Muss
- Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
| | - Claudio L Battaglini
- Department of Exercise and Sport Science, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
| | - Grant R Williams
- Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA
| |
Collapse
|
7
|
Gonzalez MC. Using Bioelectrical Impedance Analysis for Body Composition Assessment: Sorting Out Some Misunderstandings. JPEN J Parenter Enteral Nutr 2019; 43:954-955. [DOI: 10.1002/jpen.1702] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Accepted: 08/17/2019] [Indexed: 12/19/2022]
Affiliation(s)
- Maria Cristina Gonzalez
- Post‐Graduate Program in Health and BehaviorCatholic University of Pelotas Pelotas Rio Grande do Sul Brazil
- Body Composition and Nutrition (COCONUT) Study Group Pelotas Rio Grande do Sul Brazil
- Pennington Biomedical Research CenterLouisiana State University Baton Rouge Louisiana USA
| |
Collapse
|
8
|
Owari T, Miyake M, Nakai Y, Hori S, Tomizawa M, Ichikawa K, Shimizu T, Iida K, Samma S, Iemura Y, Momose H, Omori C, Otani T, Kuwada M, Hirao S, Oyama N, Nakagawa Y, Hayashi Y, Tanaka N, Fujimoto K. Clinical benefit of early treatment with bone‐modifying agents for preventing skeletal‐related events in patients with genitourinary cancer with bone metastasis: A multi‐institutional retrospective study. Int J Urol 2019; 26:630-637. [DOI: 10.1111/iju.13939] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2018] [Accepted: 02/13/2019] [Indexed: 02/07/2023]
Affiliation(s)
- Takuya Owari
- Department of Urology Nara Medical University Kashihara Nara Japan
| | - Makito Miyake
- Department of Urology Nara Medical University Kashihara Nara Japan
| | - Yasushi Nakai
- Department of Urology Nara Medical University Kashihara Nara Japan
| | - Shunta Hori
- Department of Urology Nara Medical University Kashihara Nara Japan
| | - Mitsuru Tomizawa
- Department of Urology Nara Medical University Kashihara Nara Japan
| | - Kazuki Ichikawa
- Department of Urology Nara Medical University Kashihara Nara Japan
| | - Takuto Shimizu
- Department of Urology Nara Medical University Kashihara Nara Japan
| | - Kota Iida
- Nara Urological Research and Treatment Group Nara Nara Japan
- Department of Urology Yamatotakada Municipal Hospital Yamatotakada Nara Japan
| | - Shoji Samma
- Nara Urological Research and Treatment Group Nara Nara Japan
- Department of Urology Nara Prefecture General Medical Center Nara Nara Japan
| | - Yusuke Iemura
- Nara Urological Research and Treatment Group Nara Nara Japan
- Department of Urology Nara Prefecture General Medical Center Nara Nara Japan
| | - Hitoshi Momose
- Nara Urological Research and Treatment Group Nara Nara Japan
- Department of Urology Hoshigaoka Medical Center Hirakata Osaka Japan
| | - Chihiro Omori
- Nara Urological Research and Treatment Group Nara Nara Japan
- Department of Urology Hoshigaoka Medical Center Hirakata Osaka Japan
| | - Takeshi Otani
- Nara Urological Research and Treatment Group Nara Nara Japan
- Department of Urology Matsuzaka General Hospital Matsuzaka Mie Japan
| | - Masaomi Kuwada
- Nara Urological Research and Treatment Group Nara Nara Japan
- Department of Urology Matsuzaka General Hospital Matsuzaka Mie Japan
| | - Shuya Hirao
- Nara Urological Research and Treatment Group Nara Nara Japan
- Department of Urology Hirao Hospital Kashihara Nara Japan
| | - Nobuo Oyama
- Nara Urological Research and Treatment Group Nara Nara Japan
- Department of Urology Seiwa Medical Center Ikoma Nara Japan
| | - Yoshinori Nakagawa
- Nara Urological Research and Treatment Group Nara Nara Japan
- Department of Urology Yamatotakada Municipal Hospital Yamatotakada Nara Japan
| | - Yoshiki Hayashi
- Nara Urological Research and Treatment Group Nara Nara Japan
- Department of Urology Tane General Hospital Osaka Osaka Japan
| | - Nobumichi Tanaka
- Department of Urology Nara Medical University Kashihara Nara Japan
| | | |
Collapse
|
9
|
Gonzalez MC, Barbosa-Silva TG, Heymsfield SB. Bioelectrical impedance analysis in the assessment of sarcopenia. Curr Opin Clin Nutr Metab Care 2018; 21:366-374. [PMID: 29957677 DOI: 10.1097/mco.0000000000000496] [Citation(s) in RCA: 83] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
PURPOSE OF REVIEW Bioelectrical impedance analysis (BIA) is an accepted technique to estimate low muscle mass for sarcopenia diagnosis. However, muscularity assessment from BIA relies on prediction equations, estimating different compartments according to the calibration method. Low muscle mass can be defined using different approaches. RECENT FINDINGS There is a lack of standardization on how low muscularity is defined in the context of sarcopenia. Recent studies have shown discrepant results for the estimation of low muscle mass when different prediction equations are used in the same BIA device. Different sarcopenia prevalence rates are observed if different definitions are used to identify low muscle mass. Most of the studies using BIA for diagnosing sarcopenia use the incorrect combination of specific population cut-off or a different device from the original equation. SUMMARY The lack of standardization of BIA use for assessing muscularity results in a wide range of sarcopenia prevalence rates among studies, even when conducted in the same population. As BIA equations and cut-off values are population and device-specific, results should be interpreted with caution when data from different devices are applied in equations or using cut-off values from a different population.
Collapse
Affiliation(s)
- M Cristina Gonzalez
- Postgraduate Program in Health and Behavior, Catholic University of Pelotas
- Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA
| | - Thiago G Barbosa-Silva
- Postgraduate Program in Epidemiology, Federal University of Pelotas, Pelotas, RS, Brazil
| | - Steven B Heymsfield
- Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA
| |
Collapse
|